Due to the promising results of the multimodal approach and EGCG supplementation for cognition in people with Down’s syndrome [140], the PENSA study has been launched to evaluate the effectiveness of the multimodal approach to slowing cognitive decline (SCD) in people carrying the apolipoprotein E ε4 allele with SCD [141]. The gene discussed is APOE; the disease is Schnyder corneal dystrophy.